Peptide library · Blends

What is the
“Wolverine peptide”?

“Wolverine” is a name for a pre-mixed vial, not a compound. What goes into it, which studies gave both peptides, what each one has been studied in, and why that evidence does not add up to a tested blend.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

The “Wolverine peptide” is a name sellers use for a single vial that mixes two peptides, BPC-157 and TB-500. It is not a compound. We found no controlled study of the two together in people (PubMed and ClinicalTrials.gov, 18 November 2026), so the evidence is for each peptide on its own, mostly from animal and cell studies.

Key takeaways

  • “Wolverine” is a seller name for a pre-mixed vial of BPC-157 and TB-500, not a compound. Australia’s TGA listed “the Wolverine Stack (combination of BPC-157 and TB-500)” among products it seized in New South Wales (media release, 17 August 2026).
  • We found no controlled study of the two together in people (PubMed and ClinicalTrials.gov, 18 Nov 2026). Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 rat study, a 2026 report of three patients who also received other agents, and a 2021 chart review of 16 patients, four of whom also received thymosin β4. Neither human report had a control group.
  • Each ingredient has its own evidence: mostly animal studies and small, mostly uncontrolled human studies for BPC-157; animal and cell studies for TB-500, with one placebo-controlled trial recruiting.
  • In November 2026 the TGA found no detectable TB-500 in a BPC-157 and TB-500 product from one brand, identified in a New South Wales police investigation, although its label listed it. The TGA did not call that product Wolverine.
  • HHS’s October 2026 compounding policy, a draft that is not binding and not an approval, applies only to products with a single active ingredient; HHS says that makes it easier to attribute adverse events to one substance.

01BPC-157, TB-500 and “Wolverine” compared

Two compounds and the mix that contains both, dated 18 November 2026.

QuestionBPC-157TB-500“Wolverine”
What it isA synthetic 15-amino-acid peptideIn FDA and HHS documents, a synthetic seven-amino-acid fragment of the protein thymosin β4A seller name for one vial mixing BPC-157 and TB-500
Studied as a mixNot a mixNot a mixNo study of the mix as sold; two 2026 papers gave both peptides (below)
Main evidenceMostly animal studies (T3)Animal and cell studies (T3, T4)None for the mix as sold
Human dataSmall studies, most without a control group (T2); no peer-reviewed randomised trial publishedFDA found no articles in which TB-500 was given to people; a 2026 report describes three patients given it with other agents, without a control group; one placebo-controlled trial is recruitingNo controlled study of the two together in people found
What a lab report must confirmOne identity and one amountOne identity and one amountTwo identities and two amounts in one vial
United States, Nov 2026Not approved; FDA staff recommended against 503A listing, and the advisory committee voted for it (Jul 2026)Not approved; FDA staff recommended against 503A listing, and the advisory committee voted for it (Jul 2026)HHS’s interim compounding policy requires a single active ingredient
Australia (TGA)Prescription-only medicinePrescription-only medicineTGA lab, Nov 2026: no TB-500 detected in one brand’s BPC-157 and TB-500 product, which the TGA did not call Wolverine
WADAProhibited at all times, class S0 (named)Prohibited at all times, class S2.3 (named)Both ingredients are named on the List

Each ingredient has its own page: BPC-157 and TB-500. The two side by side: BPC-157 vs TB-500.

02What is the “Wolverine peptide”?

“Wolverine” is a product name, not a molecule. Sellers use it for a single vial that holds two peptides, BPC-157 and TB-500. The amount of each is set by whoever fills the vial.

The name is on public record. In a media release of 17 August 2026 about products it seized in New South Wales, Australia’s regulator, the TGA, listed “the Wolverine Stack (combination of BPC-157 and TB-500)”. FDA’s 2026 review of BPC-157 also found websites marketing the two peptides combined in one product, including one that described its products as for research purposes only.

The two ingredients are different molecules:

  • BPC-157: a synthetic 15-amino-acid peptide, which FDA staff describe as reported to be a fragment of a protein found in gastric juice.
  • TB-500: in FDA’s 2026 review, a synthetic seven-amino-acid fragment (positions 17 to 23) of the 43-amino-acid protein thymosin β4. FDA staff write that thymosin β4 and TB-500 “are not the same substance”: see TB-500 vs thymosin beta-4.

03What studies gave BPC-157 and TB-500 together?

Three papers, one of them with thymosin β4 rather than TB-500. None is a controlled study in people, and none tested a vial sold under a name.

On 21 November 2026 a PubMed search for papers naming BPC-157 together with TB-500 or thymosin beta returned 17 results. Three gave BPC-157 with TB-500 or thymosin β4 to animals or people; none of the other 14 did. ClinicalTrials.gov lists no trial that gives both, and we found no controlled study of the two together in people.

Rats, 2026 (T3). A study from Istanbul cut and repaired the Achilles tendon in 32 rats and randomly assigned eight each to no peptide, BPC-157, TB-500, or both. At four weeks the researchers measured tendon strength and scored the tissue under the microscope. The authors call the study exploratory. Human data on this is lacking, and a study of two peptides given to rats is not a study of a pre-mixed vial.

People (T2, uncontrolled). A 2026 report describes three patients given BPC-157 and TB-500 together with other agents, without a control group. Its authors write that causality “cannot be established”.

People, 2021 (T2, uncontrolled). A retrospective chart review from one US clinic describes 16 patients with knee pain who were given BPC-157; four of them also received thymosin β4. There was no control group. FDA staff write that thymosin β4 and TB-500 “are not the same substance”.

Evidence attaches to what was studied. Whether the two peptides stay intact together in one vial, how much of each is present, and what the mix does are separate questions, and none of the papers we found measured them. The general case is on peptide blends: one vial, no shared evidence.

04What has each ingredient been studied in?

Each row is graded on its own. None of it transfers to a mixed vial.

IngredientMain evidenceIn people
BPC-157Mostly animal studies (T3)Small studies, most without a control group (T2); no peer-reviewed randomised trial published (PubMed, 18 Nov 2026).
TB-500Animal and cell studies (T3, T4). The best-known mouse study used an unacetylated version, which FDA staff say “cannot be directly extrapolated” to TB-500.FDA staff found no articles in which TB-500 was given to people. A 2026 report describes three patients given it with BPC-157 and other agents, without a control group (above). One placebo-controlled trial, NCT07487363, began recruiting in February 2026 and has no results.

Full profiles: the BPC-157 research guide and the TB-500 research guide. Every study we found that gave BPC-157 to people, with its design: BPC-157 human studies.

05Why is a two-peptide vial harder to check and to trace?

Testing. A lab report for one peptide confirms one identity and one amount. A vial with two needs each peptide identified and measured on its own, matched to the batch number. A single purity figure for the whole vial cannot show that both peptides are there, or how much of each. How to read one: how to read a COA.

What a regulator found. Australia’s TGA laboratory reported “No TB-500 detected” in a BPC-157 and TB-500 product from one brand, identified in a New South Wales police investigation, although its label listed TB-500 (advisory of 5 November 2026). The TGA’s conclusion: consumers cannot rely on these labels to know what substance, or what amount, a product contains. The TGA also warns that unapproved peptides “can cause serious health problems including liver damage, severe allergic reactions, inflammation and other health complications requiring medical attention” (media release, 17 August 2026).

Tracing a reaction. FDA’s 2026 review of BPC-157 lists three adverse-event reports from its database. One describes darkening of the skin and gums in a woman using a product labelled for research purposes that contained BPC-157 and TB-500; the reaction returned when she used it again. FDA staff judged that reaction “likely due to the drug product” but, because the product contained two peptides, could not assess whether BPC-157 played a role. Of all three reports, FDA wrote that “it is unclear whether these AEs were attributable to BPC-157”. FDA’s TB-500 review found two complaint reports about “blended TB-500 and BPC-157”, without safety assessments. None of this gives a rate: FDA notes there is no certainty that a reported event was due to the product, and that it does not receive every report. More: BPC-157 side effects.

Compounding. HHS’s interim policy of October 2026 on compounding six peptides, which is not an approval, applies only when the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. HHS gives the reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance.” BPC-157 and TB-500 are both on that list. The Federal Register notice calls the policy a draft that “is not binding”. Background: the HHS peptide policy.

06What we don’t know

  • Any effect of BPC-157 and TB-500 together in people. We found no controlled study.
  • Whether the two peptides stay intact together in one vial, or change one another. We found no published data.
  • Long-term safety of either peptide in people. FDA staff described the human studies of BPC-157 as of short duration with small samples, concluded that potential safety risks of TB-500 in humans are unknown, and wrote that each, given by injection, “may pose a significant risk for immunogenicity”.
  • What a given vial contains. A lab report shows only what the tested sample from that lot held, and only for the peptides it identifies and measures.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Therapeutic Goods Administration. TGA flexes its muscle against illegal peptides and steroids. Media release, 17 Aug 2026; read on the Internet Archive capture of 11 Oct 2026, the newest of this URL (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/news/media-releases/tga-flexes-its-muscle-aga…
  2. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 13, 24, 40–47); read 18 Nov 2026. www.fda.gov/media/193343/download
  4. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: TB-500-related bulk drug substances. Advisory committee briefing, 2026 (pp. 21–31); read 18 Nov 2026. www.fda.gov/media/193349/download
  5. Biçer O, Adanir O, Güleryüz Y, et al. [Rat Achilles tendon repair study of BPC-157, TB-500 and both together.] Jt Dis Relat Surg, 2026;37(3):822–837. PMID 42542926. pubmed.ncbi.nlm.nih.gov/42542926/
  6. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687. pubmed.ncbi.nlm.nih.gov/42876687/
  7. Lee E, Padgett B. [Retrospective chart review of patients with knee pain given BPC-157, four of them also thymosin β4.] Altern Ther Health Med, 2021;27(4):8–13. PMID 34324435 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/34324435/
  8. PubMed search: (BPC-157 OR BPC157 OR “BPC 157” OR pentadecapeptide OR bepecin) AND (TB-500 OR TB500 OR “TB 500” OR “thymosin beta” OR “thymosin beta4”), 16 results on 18 Nov and 17 on 21 Nov 2026; ClinicalTrials.gov searches for BPC-157 and TB-500 (no record names both; NCT07487363 for TB-500). Database searches, 18 and 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28BPC-157+OR+BPC157+OR+%22BPC…
  9. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read on the Internet Archive capture of 15 Nov 2026 (hhs.gov returned 403 to our fetch on 18 Nov 2026). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  10. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 18 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  11. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is the Wolverine peptide the same as BPC-157?

No. It is a name for a vial that mixes BPC-157 with TB-500, two different peptides. Each has its own evidence, and we found no controlled study of the two together in people.

Has BPC-157 with TB-500 been tested in humans?

Not in a controlled study. A 2026 report described three patients given both alongside other agents, and a 2021 chart review four patients given BPC-157 with thymosin β4, neither with a control group. ClinicalTrials.gov lists no trial of the pair (21 Nov 2026).

What is the difference between Wolverine and GLOW?

Wolverine mixes BPC-157 and TB-500. GLOW adds GHK-Cu to those two, and KLOW adds KPV on top. We found no controlled study of any of these mixes in people (PubMed and ClinicalTrials.gov, 18 Nov 2026).

Are BPC-157 and TB-500 prohibited in sport?

Yes. WADA’s Prohibited List names BPC-157 in class S0 and “Thymosin-β4 and its derivatives e.g. TB-500” in class S2.3, both prohibited at all times, in the 2026 and 2027 Lists.

What should a lab report for a two-peptide vial show?

Identity and amount for each peptide, matched to the batch number. One purity figure for the whole vial cannot show that each peptide is present.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page